Glenmark Pharma says USFDA has issued CRL for Ryaltris

The CRL cites deficiencies in the Drug Master File pertaining to one of the active pharmaceutical ingredients and in manufacturing facilities, the company said in a regulatory filing.

from Healthcare/Biotech-Industry-Economic Times http://bit.ly/2Xqi3Fd
via IFTTT